#### Confidential



**Date and Time:** Wednesday 13<sup>th</sup> July 2011, from 1000 until 1630

Minutes: Confirmed

**Guideline Development Group Meeting 6: Management of psoriasis** 

Place: National Clinical Guideline Centre, 180 Great Portland Street, London W1W

5QZ

Present: Catherine Smith (Consultant Dermatologist and Senior Lecturer, Chair)

Paul Hepple (General Practitioner)
Natasha Smeaton (General Practitioner)
Jillian Peters (Dermatology Nurse Practitioner)
Karina Jackson (Nurse Consultant, Dermatology)

Ruth Murphy (Adult and Paediatric Dermatology Consultant)
Roderick Tucker (Community Pharmacist) from item 2 onwards

David Chandler (Patient member) Claire Strudwicke (Patient member)

Jill Parnham (Guideline Operations Director, NCGC) Laura Sawyer (Senior Health Economist, NCGC) Katrina Sparrow (Senior Research Fellow, NCGC) Ellie Samarasekera (Research Fellow, NCGC) Nancy Pursey (Senior Project Manager, NCGC)

**Apologies:** 

Richard Warren (Senior Clinical Lecturer and Honorary Consultant

Dermatologist)

Bernard Higgins (Clinical Director, NCGC)
Jill Cobb (Information Scientist, NCGC)

Sarah Dundson (Guideline Commissioning Manager, NICE)

#### In attendance:

NICE Staff:		
NICE attendee 1	Natalie Boileau (Senior Project Coordinator)	

### Observers

Observer 1	Katie Jones (Project Manager, NCGC)	
Observer 2	Leanne Saxon (Research Fellow, NCGC)	

#### **Notes**

#### 1. Welcome and declarations of interest

The chair welcomed the guideline development group (GDG) to the sixth psoriasis guideline development group meeting. Apologies were received from Jill Cobb, Bernard Higgins, Sarah Dunsdon and Richard Warren. The chair requested updates to the declarations of interest and no new interests were declared. The chair reviewed the declarations of interest register and deemed that none were in conflict with the topics under discussion.

# 2. First review question for GDG6

The GDG discussed the evidence for sequencing of biologic agents.

### 3. Second review question for GDG6

The GDG discussed additional evidence for systemic drugs.

# 4. Topical treatments

The GDG signed off the questions and outcomes for the topical treatments for psoriasis.

#### 5. Review GDG5 meeting minutes

The GDG agreed the minutes that the minutes of GDG5 were a true and accurate record of the meeting.

#### 6. Any other business

None.

# Date, time and venue of the next meeting

GDG7 6<sup>th</sup> September 2011, from 1000 until 1630, Boardroom, National Clinical Guideline Centre, 5<sup>th</sup> Floor, 180 Great Portland Street, London W1W 5QZ.